Clinical Trial Update: A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase III trial of ZD4054 (Zibotentan) in non-metastatic hormone-resistant prostate cancer was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-metastatic Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• ZD4054 (zibotentan)

Snippet

Sponsor: AstraZeneca | Conditions: Prostate Cancer | Phase 3 | Status: TERMINATED | Results posted: 2012-06-01